# Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A

> **NCT01493778** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 60 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** turoctocog alfa

## Key facts

- **NCT ID:** NCT01493778
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-17
- **Primary completion:** 2017-08-16
- **Final completion:** 2018-12-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01493778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01493778, "Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01493778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*